ERBB2 and gastric cancer: The use of targeted treatments in the first‐line therapy of advanced gastric cancer is also evolving and paving the way for personalized medicine 17, although human epidermal receptor type 2 (HER2) status is currently the only validated molecular marker to influence decision‐making in advanced disease 3.